The Impact of Heterozygous KCNK3 Mutations Associated With Pulmonary Arterial Hypertension on Channel Function and Pharmacological Recovery
Michael S. Bohnen, Danilo Roman‐Campos, Cecile Terrenoire and 4 more
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease · 2017
doi:10.1161/jaha.117.006465 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Background Heterozygous loss of function mutations in the KCNK 3 gene cause hereditary pulmonary arterial hypertension ( PAH ). KCNK 3 encodes an acid‐sensitive potassium channel, which contributes to the resting potential of human pulmonary artery smooth muscle cells. KCNK 3 is widely expressed in the body, and dimerizes with other KCNK 3 subunits, or the closely related, acid‐sensitive KCNK 9 channel. Methods and Results We engineered homomeric and heterodimeric mutant and nonmutant KCNK 3 channels associated with PAH . Using whole‐cell patch‐clamp electrophysiology in human pulmonary artery smooth muscle and COS 7 cell lines, we determined that homomeric and heterodimeric mutant channels in heterozygous KCNK 3 conditions lead to mutation‐specific severity of channel dysfunction. Both wildtype and mutant KCNK 3 channels were activated by ONO ‐ RS ‐082 (10 μmol/L), causing cell hyperpolarization. We observed robust gene expression of KCNK 3 in healthy and familial PAH patient lungs, but no quantifiable expression of KCNK 9 , and demonstrated in functional studies that KCNK 9 minimizes the impact of select KCNK 3 mutations when the 2 channel subunits co‐assemble. Conclusions Heterozygous KCNK 3 mutations in PAH lead to variable loss of channel function via distinct mechanisms. Homomeric and heterodimeric mutant KCNK 3 channels represent novel therapeutic substrates in PAH . Pharmacological and pH ‐dependent activation of wildtype and mutant KCNK 3 channels in pulmonary artery smooth muscle cells leads to membrane hyperpolarization. Co‐assembly of KCNK 3 with KCNK 9 subunits may provide protection against KCNK 3 loss of function in tissues where both KCNK 9 and KCNK 3 are expressed, contributing to the lung‐specific phenotype observed clinically in patients with PAH because of KCNK 3 mutations.
Abstract licence: CC BY-NC
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.